공시 • Nov 24
Helix BioPharma Corp., Annual General Meeting, Jan 30, 2026 Helix BioPharma Corp., Annual General Meeting, Jan 30, 2026. 공시 • Aug 23
Helix BioPharma Corp. announced that it has received CAD 1.66675 million in funding Helix BioPharma Corp. announced that it has closed non-brokered private placement to issue 2,222,333 common shares at a price of CAD 0.75 for gross proceeds of CAD 1,666,749.75 on August 22, 2025. The Offering is subject to final approval of the Toronto Stock Exchange, and the Common Shares are subject to a hold period of four months and one day expiring on December 23, 2025, in accordance with applicable securities laws. In connection with the closing of the Offering, the Company will pay finders’ fees to certain eligible finders. 공시 • May 21
Helix BioPharma Corp. (TSX:HBP) completed the acquisition of Oncology assets of Laevoroc Immunology AG for CHF 5.3 million. Helix BioPharma Corp. (TSX:HBP) signed a letter of intent to acquire Oncology assets of Laevoroc Immunology AG on November 12, 2024. Helix BioPharma Corp. (TSX:HBP) entered into a Asset Purchase Agreement to acquire Oncology assets of Laevoroc Immunology AG for CHF 3.7 million on November 28, 2024. As consideration Helix will issue 16.5% of its issued and outstanding shares to Laevoroc. As on November 28, 2024, Helix would be required to issue 8.088553 million common shares based on the Helix's 49,021,536 shares currently issued and outstanding. The companies aim to close definitive agreements before year-end, upon completion of the requisite due diligence. The Transaction is subject to the approval of the Toronto Stock Exchange and certain closing conditions of transactions of a similar nature. The deal is subject to approval of the shareholders of Helix BioPharma Corp. (TSX:HBP).Helix BioPharma anticipates that Transaction will close on or around January 30, 2025 and all shares issuable in connection with the transaction will be subject to a hold period of four months and one day from the date of issuance. As on February 21, 2025, Helix BioPharma announces that its Annual General and Special Meeting for the year ended July 31, 2024, that was to be held by January 31, 2025, has been extended to March 26, 2025 to provide additional time to seek shareholder approval with respect to its proposed asset acquisition from Laevoroc Oncology AG.As on March 26, 2025 , Helix BioPharma shareholders approved the transaction.
Helix BioPharma Corp. (TSX:HBP) completed the acquisition of Oncology assets of Laevoroc Immunology AG for CHF 5.3 million on May 20, 2025. In consideration for the transaction, the Company issued 11,555,076 Consideration Shares to Laevoroc Oncology AG. 공시 • May 15
Helix BioPharma Corp. announced that it expects to receive CAD 13 million in funding Helix BioPharma Corp. announced that it will receive CAD 13 million in funding on May 14, 2025. 공시 • Mar 13
Helix BioPharma Corp. Announces Executive Appointments Helix BioPharma Corp. announced the addition of three esteemed experts in oncology and drug development to its executive team. The appointments underscore Helix's commitment to assembling a world-class team to push the limits of proven science and bring life-changing therapies to patients as soon as possible. Thomas Mehrling, MD, PhD Chief Medical Officer (CMO): Dr. Thomas Mehrling (PhD in Pharmacology and MD, University of Frankfurt) brings 20 years of experience shaping the oncology landscape, with previous roles at Takeda, Mundipharma International and Roche. His track record includes the successful introduction of groundbreaking cancer drugs across Europe, with commercial successes nearing USD 1 billion in sales. As Chief Medical Officer, Dr. Mehrling will lead Helix's clinical development strategy, beginning with Tumor Defence BreakerTM L-DOS47--a first-in-class, clinical-stage antibody- enzyme conjugate (AEC) to enhance the effectiveness of today's immune-oncology therapies for the treatment of Non-Small Cell Lung Cancer (NSCLC). Jonathan Davis, PhD Director of ADC Discovery: A leading expert in therapeutic antibodies, Dr. Davis joins Helix as Director of Antibody-Drug Conjugate (ADC) Discovery. With over 15 years of experience spearheading discovery and innovation strategies across diverse therapeutic antibody formats--including monoclonal antibodies (mAbs), multispecifics, and bi-specific ADCs (EMD Serono, Bristol-Myers Squibb, Invenra)--Dr. Davis will play a pivotal role in advancing Helix's ADC portfolio targeting Carcinoembryonic Antigen-related Cell Adhesion Molecule 6 (CECAM6). As of 2025, Helix is drawing on the latest advancements in design, conjugation, and payload technology to develop bi-specific ADCs and radionuclide drug conjugates (RDCs) for gastrointestinal, gynecological, and other solid tumors. Dr. Davis's expertise will be instrumental in translating these innovations into next-generation, targeted therapies that enhance efficacy while minimizing toxicity. Dr. Davis received his PhD from University of California, San Francisco, and completed his post-doctoral research at Harvard Medical School. Davide Guggi, PhD Chief Technology Officer (CTO): Bringing extensive Chemistry, Manufacturing, and Controls (CMC) expertise, Dr. Guggi joins Helix as Chief Technology Officer. With over a decade of experience guiding the end-to-end development of small molecules and biologics--including mAbs, ADCs, and radio-immuno conjugates--Dr. Guggi has collaborated with more than 20 global biotech firms to drive regulatory success from discovery through to new drug applications (NDA) and biologics license applications (BLA) across the US, EU, and Canada. Prior to his CMC consultancy, he led oncology business units and commercial departments at Mundipharma International and Gilead, and he received his PhD in Pharmaceutical Technology and Biotechnology from the University of Vienna. Dr. Guggi's leadership will be instrumental in ensuring the seamless clinical development of Helix's compounds while optimizing their scalability for later commercialization, positioning the Company for long-term success in bringing innovative cancer therapies to market. 공시 • Jan 10
Helix BioPharma Corp. announced that it has received CAD 3 million in funding Helix BioPharma Corp. announces that it has closed the private placement of four million common shares of the company at a price of CAD 0.75 per common share for gross proceeds of CAD 3 million. on January 9, 2025. The offering is subject to final approval of the Toronto Stock Exchange. The common shares are subject to a hold period of four months and one day expiring on May 9, 2025, in accordance with applicable securities laws. In connection with the closing, the company paid a cash fee of 105 of gross proceeds raised to an eligible finder. 